Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FIIN-1 |
Synonyms | |
Therapy Description |
FIIN-1 is an irreversible pan-FGFR inhibitor which blocks activation and downstream signaling and may inhibit transformation and proliferation in cancer cells (PMID: 20338520). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FIIN-1 | FGFR Inhibitor (Pan) 26 | FIIN-1 is an irreversible pan-FGFR inhibitor which blocks activation and downstream signaling and may inhibit transformation and proliferation in cancer cells (PMID: 20338520). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 N549K | endometrial carcinoma | sensitive | FIIN-1 | Preclinical | Actionable | In a preclinical study, FIIN-1 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K mutation in culture (PMID: 20338520). | 20338520 |
FGFR2 wild-type | endometrial carcinoma | resistant | FIIN-1 | Preclinical | Actionable | In a preclinical study, an endometrial carcinoma cell line harboring wild-type FGFR2 was resistant to FIIN-1-induced growth inhibition in culture (PMID: 20338520). | 20338520 |
FGFR2 K310R FGFR2 N549K | endometrial carcinoma | sensitive | FIIN-1 | Preclinical | Actionable | In a preclinical study, FIIN-1 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520). | 20338520 |
FGFR1 V561M | Advanced Solid Tumor | sensitive | FIIN-1 | Preclinical - Biochemical | Actionable | In a preclinical study, FIIN-1 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520). | 20338520 |
FGFR2 amp | stomach cancer | sensitive | FIIN-1 | Preclinical | Actionable | In a preclinical study, FIIN-1 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520). | 20338520 |
FGFR1 act mut | breast cancer | sensitive | FIIN-1 | Preclinical | Actionable | In a preclinical study, FIIN-1 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520). | 20338520 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|